Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
NASDAQNVAX
FormDescriptionDateFormat
S-3/APre-effective amendment to an S-3 filingDec 17, 2001Open Pre-effective amendment to an S-3 filing in HTML.Open Pre-effective amendment to an S-3 filing in DOC file.Open Pre-effective amendment to an S-3 filing in PDF file.Open Pre-effective amendment to an S-3 filing in XLS file.
S-3Simplified registration formSep 21, 2001Open Simplified registration form in HTML.Open Simplified registration form in DOC file.Open Simplified registration form in PDF file.Open Simplified registration form in XLS file.
424B3Form of prospectus reflecting facts events constituting substantive change from last formJul 26, 2001Open Form of prospectus reflecting facts events constituting substantive change from last form in HTML.Open Form of prospectus reflecting facts events constituting substantive change from last form in DOC file.Open Form of prospectus reflecting facts events constituting substantive change from last form in PDF file.Open Form of prospectus reflecting facts events constituting substantive change from last form in XLS file.
424B3Form of prospectus reflecting facts events constituting substantive change from last formJul 9, 2001Open Form of prospectus reflecting facts events constituting substantive change from last form in HTML.Open Form of prospectus reflecting facts events constituting substantive change from last form in DOC file.Open Form of prospectus reflecting facts events constituting substantive change from last form in PDF file.Open Form of prospectus reflecting facts events constituting substantive change from last form in XLS file.
8-A12GRegistration of certain classes of securities 12(g) of the Securities Exchange ActJul 9, 2001Open Registration of certain classes of securities 12(g) of the Securities Exchange Act in HTML.Open Registration of certain classes of securities 12(g) of the Securities Exchange Act in DOC file.Open Registration of certain classes of securities 12(g) of the Securities Exchange Act in PDF file.Open Registration of certain classes of securities 12(g) of the Securities Exchange Act in XLS file.
POS AMPost-effective amendment to an S-Type filingApr 4, 2001Open Post-effective amendment to an S-Type filing in HTML.Open Post-effective amendment to an S-Type filing in DOC file.Open Post-effective amendment to an S-Type filing in PDF file.Open Post-effective amendment to an S-Type filing in XLS file.
POS AMPost-effective amendment to an S-Type filingApr 4, 2001Open Post-effective amendment to an S-Type filing in HTML.Open Post-effective amendment to an S-Type filing in DOC file.Open Post-effective amendment to an S-Type filing in PDF file.Open Post-effective amendment to an S-Type filing in XLS file.
POS AMPost-effective amendment to an S-Type filingApr 4, 2001Open Post-effective amendment to an S-Type filing in HTML.Open Post-effective amendment to an S-Type filing in DOC file.Open Post-effective amendment to an S-Type filing in PDF file.Open Post-effective amendment to an S-Type filing in XLS file.
S-3Simplified registration formJan 4, 2001Open Simplified registration form in HTML.Open Simplified registration form in DOC file.Open Simplified registration form in PDF file.Open Simplified registration form in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.